Abstract
A mechanistic model including the role of platelets is proposed for clot formation and growth in plasma in vitro. Initiation of clot formation is by the addition of tissue factor, and initiation via the intrinsic pathway is neglected. Activation of zymogens follows the extrinsic pathway cascade and reactions on platelet membranes are included. Platelet activation occurs due to thrombin and also due to other activated platelets. Inhibition of the active clotting factors is by ATIII and TFPI, whereas inhibition due to APC is not relevant in the conditions modeled. The model predictions matched existing data for thrombin production in synthetic plasma. The model predicts that inhibition of platelet-driven activation of platelets has a major effect on concentration of activated platelets in PRP, normal plasma and PPP. Inhibition of platelet activation by (other activated) platelets significantly delays thrombin production in PRP and normal plasma as compared to that by thrombin. Further, sensitivity analysis shows that the model is most sensitive to the activation of platelet membrane-bound factor X by the intrinsic tenase complex.
Similar content being viewed by others
References
Luan D, Zai M and Varner J D 2007 Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput. Biol. 3(7): e142
Panteleev M A, Sveshnikova A N, Belyaev A V, Nechipurenko D Y, Gudich I, Obydenny S I, Dovlatova N, Fox S C and Holmuhamedov E L 2014 Systems biology and systems pharmacology of thrombosis. Math. Model. Nat. Phenom. 9(6): 4–16
Mann K G 2012 Is there value in kinetic modeling of thrombin generation? yes. J. Thromb. Haemost. 10(8): 1463–1469
Bates S M and Weitz J I 2005 Coagulation assays. Circulation 112(4): e53–e60
Walenga J M and Hoppensteadt D A 2004 Monitoring the new antithrombotic drugs. In: Seminars in thrombosis and hemostasis, vol. 30, pp. 683–695. Thieme Medical, New York, USA
Ataullakhanov F I and Panteleev M A 2005 Mathematical modeling and computer simulation in blood coagulation. Pathophys. Haemost. Thromb. 34(2–3): 60–70
Monroe D M, Hoffman M and Roberts H R 2002 Platelets and thrombin generation. Arterioscler. Thromb. Vasc. Biol. 22: 1381–1389
Kuharsky A L and Fogelson A L 2001 Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. Biophys. J. 80(3): 1050–1074
Fogelson A L, Hussain Y H and Leiderman K 2012 Blood clot formation under flow: the importance of factor xi depends strongly on platelet count. Biophys. J. 102(1): 10–18
Hockin M F, Jones K C, Everse S J and Mann K G 2002 A model for the stoichiometric regulation of blood coagulation. J. Biol. Chem. 277(21): 18322–18333
Anand M, Rajagopal K and Rajagopal K R 2008 A model for the formation, growth, and lysis of clots in quiescent plasma: a comparison between the effects of antithrombin iii deficiency and protein c deficiency. J. Theor. Biol. 253(4): 725–738
Furie B and Furie B C 2008 Mechanisms of thrombus formation. N. Eng. J. Med. 359(9): 938–949
Monroe D M and Hoffman M 2006 What does it take to make the perfect clot? Arterioscler. Thromb. Vasc. Biol. 26(1): 41–48
Jesty J 2001 Blood coagulation. Wiley, New York
Tracy P B, Eide L L, Bowie E J, Mann K G and Tracy B 1982 Radioimmunoassay of factor V in human plasma and platelets. Blood 60: 59–63
Lipscomb M S and Walsh P N 1979 Human platelets and factor xi: localization in platelet membranes of factor xi-like activity and its functional distinction from plasma factor xi. J. Clin. Invest. 63(5): 1006
Wood J P, Silveira J R, Maille N M, Haynes L M and Tracy P B 2011 Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity. Blood 117(5): 1710–1718
van’t Veer C and Mann K G 1997 Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-iii, and heparin cofactor-ii. J. Biol. Chem. 272(7): 4367–4377
Panteleev M A, Zarnitsina V I and Ataullakhanov F I 2002 Tissue factor pathway inhibitor. Eur. J. Biochem. 269(8): 2016–2031
Butenas S and Mann K G 2002 Blood coagulation. Biochemistry (Moscow) 67(1): 3–12
Hoffman R, Benz E J, Silberstein L E, Heslop H, Weitz J and Anastasi J 2012 Hematology: basic principles and practice, expert consult premium edition–Enhanced online features. Elsevier, Amsterdam
Diamond S L 2013 Systems biology of coagulation. J. Thromb. Haemost. 11(s1): 224–232
Chatterjee M S, Denney W S, Jing H and Diamond S L 2010 Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood. PLoS Comput. Biol. 6(9): e1000950
Jones K C and Mann K G 1994 A model for the tissue factor pathway to thrombin. J. Biol. Chem. 269(37): 23367–23373
Mann K G, Butenas S and Brummel K 2003 The dynamics of thrombin formation. Arterioscler. Thromb. Vasc. Biol. 23(1): 17–25
Lourens Marcel A J 2007 A mathematical model for platelet adhesion and activation. Master thesis
Tokarev A, Sirakov I, Panasenko G, Volpert V, Shnol E, Butylin A and Ataullakhanov F 2012 Continuous mathematical model of platelet thrombus formation in blood flow. Russian J. Numer. Anal. Math. Model. 27(2): 191–212
Ataullakhanov F I, Krasotkina Yu V, Sarbash V I, Volkova R I, Sinauridse E I and Kondratovich A Yu 2002 Spatio-temporal dynamics of blood coagulation and pattern formation: an experimental study. Int. J. Bifurc. Chaos 12(09): 1969–1983
Ataullakhanov F I, Zarnitsina V I, Pokhilko A V, Lobanov A I and Morozova O L 2002 Spatio-temporal dynamics of blood coagulation and pattern formation: a theoretical approach. Int. J. Bifurc. Chaos 12(09): 1985–2002
Moiseyev G, Givli S and Bar-Yoseph P Z 2013 Fibrin polymerization in blood coagulationa statistical model. J. Biomech. 46(1): 26–30
Orfeo T, Butenas S, Brummel-Ziedins K E and Mann K G 2005 The tissue factor requirement in blood coagulation. J. Biol. Chem. 280(52): 42887–42896
Balandina A N, Shibeko A M, Kireev D A, Novikova A A, Shmirev I I, Panteleev M A and Ataullakhanov F I 2011 Positive feedback loops for factor v and factor vii activation supply sensitivity to local surface tissue factor density during blood coagulation. Biophys. J. 101(8): 1816–1824
Beard Daniel A 2012 Biosimulation: simulation of living systems. Cambridge University Press, Cambridge.
Rand M D, Lock J B, Van’t Veer C, Gaffney D P and Mann K G 1996 Blood clotting in minimally altered whole blood. Blood 88(9): 3432–3445
Lawson J H, Butenas S and Ribarik N 1993 Complex-dependent inhibition of factor VIIa by antithrombin III and Heparin. J. Biol. Chem. 268(2): 767–770
Mann K G, Nesheim M E, Church W R, Haley P and Krishnaswamy S 1990 Surface-dependent reactions of the vitamin k-dependent enzyme complexes. Blood 76(1): 1–16
Wiebe E M, Stafford A R, James C, Weitz J I and Fredenburgh J C 2003 Enzyme catalysis and regulation: mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. J. Biol. Chem. 278(37): 35767–35774
Krishnaswamy S, Jones K C and Mann K G 1988 Prothrombinase complex assembly. kinetic mechanism of enzyme assembly on phospholipid vesicles. J. Biol. Chem. 263(8): 3823–3834
Raut S, Weller L and Barrowcliffe T W 1999 Phospholipid binding of factor viii in different therapeutic concentrates. Br. J. Haematol. 107(2): 323–329
Anand M, Rajagopal K and Rajagopal K R 2003 A model incorporating some of the mechanical and biochemical factors underlying clot formation and dissolution in flowing blood. J. Theor. Med. 5(3–4): 183–218
Ahmad S S, Rawala-Sheikh R and Walsh P N 1989 Comparative interactions of factor ix and factor ixa with human platelets. J. Biol. Chem. 264(6): 3244–3251
Ahmad S S, Scandura J M and Walsh P N 2000 Structural and functional characterization of platelet receptor-mediated factor viii binding. J. Biol. Chem. 275(17): 13071–13081
Butenas S, van’t Veer C and Mann K G 1999 Normal thrombin generation. Blood 94(7): 2169-2178
Marx R E 2001 Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 10(4): 225–228
Sultan A 2010 Five-minute preparation of platelet-poor plasma for routine coagulation testing. East. Mediterr. Health J. 16(2): 233–236
Danforth C M, Orfeo T, Mann K G, Brummel-Ziedins K E and Everse S J 2009 The impact of uncertainty in a blood coagulation model. Math. Med. Biol. 26(4): 323–336
Naidu P P and Anand M 2014 Importance of viiia inactivation in a mathematical model for the formation, growth, and lysis of clots. Math. Model. Nat. Phenom. 9(06): 17–33
Hemker H C and Ataullakhanov F I 2005 Good mathematical practice: simulation of the hemostatic–thrombotic mechanism, a powerful tool but one that must be used with circumspection. Pathophys. Haemost. Thromb. 34(2–3): 55–57
Butenas S, Cawthern K M, van’t Veer C, DiLorenzo M E, Lock J B and Mann K G 2001 Antiplatelet agents in tissue factor-induced blood coagulation. Blood 97(8): 2314–2322
Sequeira A and Bodnár T 2014 Blood coagulation simulations using a viscoelastic model. Math. Model. Nat. Phenom. 9(6): 34–45
Butenas S and Mann K G 1996 Kinetics of human factor VII activation. Biochemistry 35(6): 1904–1910
Butenas S, Orfeo T and Mann K G 2009 Tissue factor in coagulation which? where? when? Arterioscler. Thromb. Vasc. Biol. 29(12): 1989–1996
Bauer K A, Kass B L, ten Cate H, Hawiger J J and Rosenberg R D 1990 Factor ix is activated in vivo by the tissue factor mechanism. Blood 76(4): 731–736
Pieters J, Willems G, Hemker H C and Lindhout T 1988 Inhibition of factor LXa and factor X, by antithrombin III/heparin during factor X activation. J. Biol. Chemi. 263(30): 15313–15318
Krishnaswamy S, Williams E B and Mann K G 1986 The binding of activated protein C to factors V and Va. J. Biol. Chem. 261(21): 9684–9693
van’t Veer C, Hackeng T M, Delahaye C, Sixma J J and Bouma B N 1994 Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. Blood 84: 1132–1142
Heemskerk J W M, Bevers E M and Lindhout T 2002 Platelet activation and blood coagulation. Thromb. Haemost. Stuttgart. 88(2): 186–194
Neuenschwander P F and Jesty J 1988 A comparison of phospholipid and platelets in the activation of human factor VIII by thrombin and factor Xa, and in the activation of factor X. Blood 72(5): 1761–1770
Fay P J 2004 Activation of factor viii and mechanisms of cofactor action. Blood Rev. 18(1): 1–15
Neuenschwander P F and Jesty J 1992 Thrombin-activated and factor xa-activated human factor viii: differences in cofactor activity and decay rate. Arch. Biochem. Biophys. 296(2): 426–434
Monkovic D D and Tracy P B 1990 Activation of human factor V by factor Xa and thrombin. Biochemistry 29(5): 1118–1128
Mann K G 2003 Thrombin formation. CHEST J. 124(3 Suppl): 4S–10S
Acknowledgements
MS was supported by the MHRD Fellowship for Research Scholars administered by IIT Hyderabad.
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix 1: Model reactions
Appendix 2: Description of reactions
1.1 Generation and depletion of factors VIIa, VII:
Tissue Factor (TF), an integral membrane protein gets exposed to blood upon blood vessel injury. It binds clotting factor VII/VIIa present in the plasma. Free, and tissue factor-bound factor VII is activated by factors IIa and Xa [51]. The TF–VIIa complex initiates the “extrinsic pathway” of blood coagulation. Clot formation proceeds by activation of zymogens factor IX and factor X [52]. TFPI exhibits a Xa-dependent inhibition of TF-VIIa [19].
1.2 Generation and depletion of factors IXa, IX:
While activation of factor IX by the tissue factor–factor VIIa complex is predominant and requires a membrane surface, that by factor XI is also important and is independent of a membrane surface [21, 53]. However, since we assume that the intrinsic pathway is inhibited, we neglect the role of factor XI in the present model. Inactivation of the activated factor IX occurs by the action of ATIII in the plasma [37, 54].
1.3 Generation and depletion of factors Xa, X:
Activation of factor X occurs by the tissue factor–factor VIIa complex, i.e., the extrinsic tenase complex (via extrinsic pathway), and by the factor VIIIa–factor IXa complex, i.e., the intrinsic tenase complex (via intrinsic pathway). Activated factor X then combines with activated factor V to form the platelet membrane-bound prothrombinase complex [12, 55]. Following the inactivation of factor Va (in the prothrombinase complex) by APC, dissociation of factor Xa from the membrane surface occurs. The dissociated factor Xa is then removed by flow and/or inactivated by ATIII and TFPI in plasma [56].
1.4 Generation and depletion of factors IIa, II:
Activation of the zymogen prothrombin to the enzyme thrombin occurs predominantly by the action of prothrombinase on activated membrane surface [20]. However, small amounts of prothrombin are also activated in plasma at a low rate by factor Xa [10]. Thrombin is primarily inhibited by ATIII [37].
1.5 Generation and depletion of activated and resting platelets:
The tissue factor and collagen exposed due to disruption of sub-endothelium lead to activation of platelets. In addition to converting fibrinogen to fibrin, thrombin plays a major role in activating platelets [12, 57]. Also, platelets are constitutively activated once they come in contact with other activated platelets in the plasma or on the sub-endothelial surface [57].
1.6 Generation and depletion of factors VIIIa, VIII:
Thrombin-activation of factor VIII does not necessarily require a membrane surface. However, activation of factor VIII by activated factor X, which is also an important reaction, requires activated platelets [58, 59]. On being activated, factor VIII shows cofactor activity in conjunction with activated factor IX [21]. Inhibition of activated factor VIII occurs due to the proteolytic attack by activated protein C (APC) on the membrane surface, apart from spontaneous decay [60].
1.7 Formation and dissociation of intrinsic tenase complex (\(\hbox {VIIIa}^{m}\) : \(\hbox {IXa}^{m}\)):
On activation, activated factor IX combines with its active cofactor, factor VIIIa, and forms intrinsic tenase complex on the surface of activated platelets. This procoagulant complex then activates factor X via the intrinsic pathway [21, 25].
1.8 Generation and depletion of factor Va, V:
Activation of factor V to its cofactor state, factor Va, occurs by the action of thrombin [7], as well as by that of factor Xa (on the membrane surface) [61]. Competitive binding of APC to factor Va (which we have not included) followed by cleavage leads to inactivation of factor Va [62], apart from spontaneous decay just like factor VIIIa.
1.9 Formation and dissociation of prothrombinase complex (\(\hbox {Xa}^{m}\) : \(\hbox {Va}^{m}\)):
Factor Va, the cofactor of factor Xa, binds it on the platelet membrane surface giving rise to the prothrombinase complex which converts prothrombin to thrombin [55, 62].
1.10 Generation and depletion of ATIII and TFPI:
While ATIII is a major physiologic inhibitor of almost all serine proteases produced during the process of blood coagulation process, TFPI mainly targets factor Xa and the TF–VIIa-factor Xa complex. Heparin-catalyzed ATIII-inhibition of factors IX, X and II is faster than the uncatalyzed reaction [54]. Since heparin is released from endothelial cells upon injury, in our case, we assume that the amount of heparin present is negligible as endothelial cells are not present in plasma in vitro. Inactivation by ATIII and TFPI occurs once the clotting enzymes escape into the plasma from the site of thrombus formation [20].
Rights and permissions
About this article
Cite this article
Susree, M., Anand, M. A mathematical model for in vitro coagulation of blood: role of platelet count and inhibition. Sādhanā 42, 291–305 (2017). https://doi.org/10.1007/s12046-017-0602-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12046-017-0602-3